收藏切换
Analysis and thinking on the reform of clinical trial data supervision in China
收藏切换
Lianghui TONG1, Fan ZHANG2, Tanlin SUN1, Yangyang ZHANG1, Zhijuan ZHANG1, Ruilin SONG1, 3, *
World Clinical Drug | 2023, 44(8) : 882 - 890
Less
收藏切换
World Clinical Drug | 2023, 44(8): 882-890
• Pharmacy administration •
Analysis and thinking on the reform of clinical trial data supervision in China
Full
Lianghui TONG1, Fan ZHANG2, Tanlin SUN1, Yangyang ZHANG1, Zhijuan ZHANG1, Ruilin SONG1, 3, *
Affiliations
  • 1.Center for Policy Research,China Pharmaceutical Innovation and Research Development Association, Beijing 100007, China
  • 2.Institude of Regulatory, China Pharmaceutical University, Nanjing 211198, Jiangsu Province, China
  • 3.The Research Center of National Drug Policy and Ecosystem, China Pharmaceutical University, Nanjing 211198, Jiangsu Province, China
Published: 2023-08-10 doi: 10.13683/j.wph.2023.08.019
Outline
收藏切换

In recent years, China has carried out in-depth clinical trial supervision reform and established a clinical trial management system that is in line with international standards. However, a minority from the United States and other western countries still take the news reports voluntarily disclosed by Chinese media on the self-inspection & verification of clinical trials in 2016 as the basis, ignoring the achievements of China's drug regulatory reform, questioning the quality of existing pharmaceutical clinical trials in China, which has a negative affect the internationalization development of China's pharmaceutical innovation. This paper conducted an in-depth study on the work of launching background of the self-inspection & verification of clinical trial data in 2015 and the relevant data in the 2017 summary report, revealed the actual situation of the work at that time, analyzed the policy background behind the problems, and put forward policy recommendations to continue to optimize the management of pharmaceutical clinical trials.

clinical trial data  /  self-inspection & verification  /  drug registration classification  /  clinical trial management  /  the International Council of Harmonisation of Technical Requirements for Pharmaceuticals for Human Use
佟梁慧, 张帆, 孙潭霖, 张洋洋, 张志娟, 宋瑞霖. 中国临床试验数据监管改革的分析与思考. 世界临床药物, 2023 , 44 (8) : 882 -890 . DOI: 10.13683/j.wph.2023.08.019
Lianghui TONG, Fan ZHANG, Tanlin SUN, Yangyang ZHANG, Zhijuan ZHANG, Ruilin SONG. Analysis and thinking on the reform of clinical trial data supervision in China[J]. World Clinical Drug, 2023 , 44 (8) : 882 -890 . DOI: 10.13683/j.wph.2023.08.019
Year 2023 volume 44 Issue 8
5
0
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2023.08.019
  • Receive Date:2023-02-21
  • Online Date:2026-11-18
  • Published:2023-08-10
Article Data
Affiliations
History
  • Received:2023-02-21
Affiliations
    1.Center for Policy Research,China Pharmaceutical Innovation and Research Development Association, Beijing 100007, China
    2.Institude of Regulatory, China Pharmaceutical University, Nanjing 211198, Jiangsu Province, China
    3.The Research Center of National Drug Policy and Ecosystem, China Pharmaceutical University, Nanjing 211198, Jiangsu Province, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2023.08.019
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT